Current and emerging therapies in large-vessel vasculitis (Q50082820)

24 February 2018

title

Current and emerging therapies in large-vessel vasculitis (English)

1 reference

24 February 2018

author name string

Tanaz A Kermani

series ordinal

1

1 reference

24 February 2018

Bhaskar Dasgupta

series ordinal

2

1 reference

24 February 2018

publication date

24 October 2017

1 reference

24 February 2018

published in

Rheumatology

1 reference

24 February 2018

2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides

cites work

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEX385

Clinical features and radiological findings in large vessel vasculitis: are Takayasu arteritis and giant cell arteritis 2 different diseases or a single entity?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEX385

Extra-cranial giant cell arteritis and Takayasu arteritis: How similar are they?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEX385

Development of outcome measures for large-vessel vasculitis for use in clinical trials: opportunities, challenges, and research agenda

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEX385

Polymyalgia Rheumatica and Giant Cell Arteritis: A Systematic Review

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEX385

Adverse outcomes of antiinflammatory therapy among patients with polymyalgia rheumatica

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEX385

Corticosteroid-related adverse events in patients with giant cell arteritis: A claims-based analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEX385

Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEX385

Serious adverse effects associated with glucocorticoid therapy in patients with giant cell arteritis (GCA): A nested case-control analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEX385

Epidemiology and mortality in 220 patients with polymyalgia rheumatica.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEX385

Incidence of diagnosed polymyalgia rheumatica and temporal arteritis in the United Kingdom, 1990-2001.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEX385

2012 Provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEX385

2012 provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEX385

BSR and BHPR guidelines for the management of polymyalgia rheumatica

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEX385

2015 Recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEX385

Treatment of polymyalgia rheumatica: a systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEX385

Current evidence for therapeutic interventions and prognostic factors in polymyalgia rheumatica: a systematic literature review informing the 2015 European League Against Rheumatism/American College of Rheumatology recommendations for the management

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEX385

An initially double-blind controlled 96 week trial of depot methylprednisolone against oral prednisolone in the treatment of polymyalgia rheumatica

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEX385

Can methotrexate be used as a steroid sparing agent in the treatment of polymyalgia rheumatica and giant cell arteritis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEX385

Prednisone plus methotrexate for polymyalgia rheumatica: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEX385

Azathioprine in giant cell arteritis/polymyalgia rheumatica: a double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEX385

Genetic markers of disease susceptibility and severity in giant cell arteritis and polymyalgia rheumatica.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEX385

Serum markers associated with disease activity in giant cell arteritis and polymyalgia rheumatica

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEX385

Serum interleukin-6 receptor in polymyalgia rheumatica: a potential marker of relapse/recurrence risk.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEX385

Serum cytokines and steroidal hormones in polymyalgia rheumatica and elderly-onset rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEX385

Effect of etanercept in polymyalgia rheumatica: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEX385

Sustained remission after long-term biological therapy in patients with large vessel vasculitis: an analysis of ten cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEX385

Efficacy of first-line tocilizumab therapy in early polymyalgia rheumatica: a prospective longitudinal study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEX385

Brief Report: A Prospective Open-Label Phase IIa Trial of Tocilizumab in the Treatment of Polymyalgia Rheumatica

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEX385

Tocilizumab is effective against polymyalgia rheumatica: experience in 13 intractable cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEX385

Tocilizumab in giant cell arteritis: Multicenter open-label study of 22 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEX385

Glucocorticoid-resistant polymyalgia rheumatica: pretreatment characteristics and tocilizumab therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEX385

Effective control of polymyalgia rheumatica with tocilizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEX385

Tocilizumab: a novel humanized anti-interleukin 6 (IL-6) receptor antibody for the treatment of patients with non-RA systemic, inflammatory rheumatic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEX385

Tocilizumab for polymyalgia rheumatica: report of two cases and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEX385

Interleukin-6: a promising target for the treatment of polymyalgia rheumatica or giant cell arteritis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEX385

Epidemiology of giant cell arteritis and polymyalgia rheumatica

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEX385

Vascular involvement in patients with giant cell arteritis determined by duplex sonography of 2x11 arterial regions

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEX385

Repetitive 18F-fluorodeoxyglucose positron emission tomography in giant cell arteritis: a prospective study of 35 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEX385

Large-vessel involvement in recent-onset giant cell arteritis: a case-control colour-Doppler sonography study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEX385

Large vessel involvement in biopsy-proven giant cell arteritis: prospective study in 40 newly diagnosed patients using CT angiography.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEX385

Positron emission tomography assessment of large vessel inflammation in patients with newly diagnosed, biopsy-proven giant cell arteritis: a prospective, case-control study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEX385

Ultrasound of proximal upper extremity arteries to increase the diagnostic yield in large-vessel giant cell arteritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEX385

Large-vessel giant cell arteritis: a cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEX385

Prognosis of large-vessel giant cell arteritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEX385

EULAR recommendations for the management of large vessel vasculitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEX385

Concise guidance: diagnosis and management of giant cell arteritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEX385

Management of giant cell arteritis: Recommendations of the French Study Group for Large Vessel Vasculitis (GEFA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEX385

Daily and alternate-day corticosteroid regimens in treatment of giant cell arteritis: comparison in a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEX385

A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEX385

Combined treatment of giant-cell arteritis with methotrexate and prednisone. a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEX385

Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEX385

Is there a place for cyclophosphamide in the treatment of giant-cell arteritis? A case series and systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEX385

Steroid-sparing effect and toxicity of dapsone treatment in giant cell arteritis: A single-center, retrospective study of 70 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEX385

Newly diagnosed vs. relapsing giant cell arteritis: Baseline data from the GiACTA trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEX385

Clinical relevance of persistently elevated circulating cytokines (tumor necrosis factor alpha and interleukin-6) in the long-term followup of patients with giant cell arteritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEX385

Th17 and Th1 T-cell responses in giant cell arteritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEX385

Tissue and serum markers of inflammation during the follow-up of patients with giant-cell arteritis--a prospective longitudinal study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEX385

IFN-γ and IL-17: the two faces of T-cell pathology in giant cell arteritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEX385

Adalimumab for steroid sparing in patients with giant-cell arteritis: results of a multicentre randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEX385

Tocilizumab in Giant Cell Arteritis: A Multicenter Retrospective Study of 34 Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEX385

Long-term efficacy and safety of tocilizumab in giant cell arteritis and large vessel vasculitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEX385

Tocilizumab for giant cell arteritis: an amazing result.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEX385

Ultrasonographic resolution of the vessel wall oedema with modest clinical improvement in a large-vessel vasculitis patient treated with tocilizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEX385

Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEX385

A Randomized, Double-Blind Trial of Abatacept (CTLA-4Ig) for the Treatment of Giant Cell Arteritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEX385

Current Clinical Features of New Patients With Takayasu Arteritis Observed From Cross-Country Research in Japan: Age and Sex Specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEX385

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEX385

Takayasu arteritis in southern Sweden

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEX385

Mycophenolate mofetil in Takayasu's arteritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEX385

Mycophenolate mofetil reduces disease activity and steroid dosage in Takayasu arteritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEX385

Takayasu arteritis in children: preliminary experience with cyclophosphamide induction and corticosteroids followed by methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEX385

Treatment of Pediatric Takayasu arteritis with infliximab and cyclophosphamide: experience from an American-Brazilian cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEX385

Pathogenesis of Takayasu's arteritis: a 2011 update

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEX385

Profiles of serum cytokine levels in Takayasu arteritis patients: Potential utility as biomarkers for monitoring disease activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEX385

Takayasu arteritis is characterised by disturbances of B cell homeostasis and responds to B cell depletion therapy with rituximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEX385

Anti-tumor necrosis factor therapy in patients with difficult to treat Takayasu arteritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEX385

Anti-tumour necrosis factor therapy in patients with refractory Takayasu arteritis: long-term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEX385

Efficacy of Biological-Targeted Treatments in Takayasu Arteritis: Multicenter, Retrospective Study of 49 Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEX385

TNF inhibitors appear to inhibit disease progression and improve outcome in Takayasu arteritis; an observational, population-based time trend study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEX385

Efficacy and safety of anti-interleukin 6 receptor monoclonal antibody (tocilizumab) in Colombian patients with Takayasu arteritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEX385

Rapid control of disease activity by tocilizumab in 10 'difficult-to-treat' cases of Takayasu arteritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEX385

Tocilizumab for the treatment of patients with refractory Takayasu arteritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEX385

Treatment of refractory Takayasu arteritis with tocilizumab: 7 Italian patients from a single referral center.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEX385

Tocilizumab in refractory Takayasu arteritis: a case series and updated literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEX385

Tocilizumab for Treating Takayasu's Arteritis and Associated Stroke: A Case Series and Updated Review of the Literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEX385

Sustained inflammation of the aortic wall despite tocilizumab treatment in two cases of Takayasu arteritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEX385

Development of a Provisional Core Domain Set for Polymyalgia Rheumatica: Report from the OMERACT 12 Polymyalgia Rheumatica Working Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEX385

Update on Outcome Measure Development for Large Vessel Vasculitis: Report from OMERACT 12

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEX385

Drug-associated polymyalgia rheumatica/giant cell arteritis occurring in two patients after treatment with ipilimumab, an antagonist of ctla-4

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEX385

Th1 and Th17 Cytokines Drive Inflammation in Takayasu Arteritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEX385

Ustekinumab for the treatment of refractory giant cell arteritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/RHEUMATOLOGY/KEX385

10.1093/RHEUMATOLOGY/KEX385

21 January 2018

Identifiers

DOI

1 reference

24 February 2018

1 reference

24 February 2018